Search

Displaying results 6661 - 6670 of 10000 in total
  1. Target

    Nuclear receptor subfamily 4 group A member 3

    go.drugbank.com/bio_entities/BE0008998
    TargetHumans

    Induces gene expression by binding as monomers to the NR4A1 response element (NBRE) 5'-AAAAGGTCA-3' site and as homodimers to the Nur response element (NurRE) site in the promoter of their regulated target

    Polypeptides: Nuclear receptor subfamily 4 group A member 3
  2. Indication

    Acute Hepatitis C Genotype 3

    go.drugbank.com/conditions/DBCOND0173310
    Drugs: Glecaprevir · Pibrentasvir
    Synonyms: Genotype 3 Acute Hepatitis C, Acute Hepatitis C Genotype 3
  3. Drug

    Colloidal oatmeal

    go.drugbank.com/drugs/DB11286
    ApprovedNutraceutical

    It is available in topical products as a skin soothing agent. … Colloidal oatmeal is a FDA-approved skin protectant that temporarily protects and helps relieve minor skin irritation and itching due to rashes, eczema, poison ivy, oak, sumac, or insect bites.

    Mixtures: Pediadermics Eczema 3, 5% Oat Facial CleanserProducts: 3-In-1 Relief CVS, ZO MEDICAL 3-STEP PEEL Kit
  4. Drug

    Hexoprenaline

    go.drugbank.com/drugs/DB08957
    ApprovedWithdrawn

    Hexoprenaline is a stimulant of beta 2 adrenergic receptors. It is used as a bronchodilator, antiasthmatic, and tocolytic agent.

    Categories: Adrenergic beta-2 Receptor Agonists, Selective Beta 2-adrenergic AgonistsProducts: Gynipral 10 µg/2 ml - Ampullen, Gynipral 25 µg - Konzentrat zur Infusionsbereitung
  5. Drug

    Valbenazine

    go.drugbank.com/drugs/DB11915
    ApprovedInvestigational

    The reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg.[L47910] … This approval was supported by positive results in multiple trials, including the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open-label extension trial.

    Categories: Heterocyclic Compounds, 2-Ring, Vesicular Monoamine Transporter 2 InhibitorProducts: REMLEAS HARD CAPSULES 40 MG, REMLEAS™ hard capsules 40mg
  6. Drug

    Doxofylline

    go.drugbank.com/drugs/DB09273
    Investigational

    In contrast with other xanthine derivatives, doxofylline does not significantly bind to adenosine alpha-1 or alpha-2 receptors and lacks stimulating effects. … Doxofylline is a methylxanthine derivative with the presence of a dioxolane group in position 7.

    Mixtures: MUCOFIX 600/200 MG EFERVESAN, 5 ADET, MUCOFIX 1200/400 MG EFERVESAN TABLET, 5 ADETCategories: Adrenergic beta-2 Receptor Agonists, Heterocyclic Compounds, 2-Ring
  7. Drug

    Trastuzumab emtansine

    go.drugbank.com/drugs/DB05773
    ApprovedInvestigational

    Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent … T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis.

    Categories: HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors, P-glycoprotein substrates with a Narrow Therapeutic IndexSynonyms: T-DM1
  8. Drug

    Econazole

    go.drugbank.com/drugs/DB01127
    Approved

    A broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.

    Mixtures: Econazole Nitrate 1% / Niacinamide 4%, 071023 Econazole Nitrate 1% / Niacinamide 4%Categories: P-glycoprotein inhibitors, Heterocyclic Compounds, 1-Ring
  9. Drug

    Perazine

    go.drugbank.com/drugs/DB12710
    ApprovedWithdrawn

    Perazine has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders, among others.

    Categories: Heterocyclic Compounds, 3-RingProducts: PERAZIN-NEURAX 25 MG, PERAZIN-NEURAX 100 MG
  10. Drug

    Cabozantinib

    go.drugbank.com/drugs/DB08875
    ApprovedInvestigational

    Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. … [L15123] In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019

    Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: CABOMETYX 20 MG FİLM KAPLI TABLET, 30 ADET, CABOMETYX 40 MG FİLM KAPLI TABLET, 30 ADET